ArticleMedicine2026
Serum vitamin B12 levels and 90-day outcomes in hospitalized patients with dementia: A cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated serum vitamin B12 levels have emerged as a paradoxical prognostic marker associated with increased mortality across various clinical settings, yet their significance in hospitalized dementia patients remains unexplored. Given the high vulnerability of this population, we aimed to investigate the association between elevated serum vitamin B12 levels and all-cause mortality. This retrospective cohort study evaluated 90-day outcomes in hospitalized adults with dementia who had serum vitamin B12 levels measured within 7 days of admission (2010-2024). Patients were categorized into exposure (vitamin B12 ≥ 900 pg/mL) and control (300-900 pg/mL) groups. Propensity score matching balanced baseline characteristics, including demographics, comorbidities, and laboratory parameters. The primary endpoint was all-cause mortality within 90 days. Secondary endpoints comprised sepsis, pneumonia, urinary tract infection, and admission to the intensive care unit (ICU). Sensitivity analyses restricted the cohort to patients with unspecified dementia and to patients with a dementia diagnosis established at least 1 year before the index admission. After propensity score matching, 16,513 patients were included in each cohort. Elevated vitamin B12 was significantly associated with increased 90-day mortality (10.9% vs 8.3%; odds ratio [OR] 1.36, 95% confidence interval [CI] 1.26-1.46, P < .001), sepsis (4.2% vs 3.0%; OR 1.43, 95% CI 1.27-1.61, P < .001), pneumonia (8.3% vs 6.6%; OR 1.28, 95% CI 1.18-1.39, P < .001), and ICU admission (3.9% vs 3.0%; OR 1.31, 95% CI 1.16-1.47, P < .001). No association was observed with urinary tract infection (OR 0.97, 95% CI 0.90-1.04, P = .377). The findings remained robust across sensitivity and subgroup analyses. Elevated vitamin B12 levels are associated with increased short-term mortality, infectious complications, and ICU admission in hospitalized patients with dementia. This readily available biomarker may serve as a potential indicator for risk stratification in this vulnerable population. However, given the observational nature of this study, future prospective studies are warranted to confirm these findings and elucidate the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.